Navigation Links
Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution Agreement

AUSTIN, Texas, May 28, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has extended their global supply and distribution agreement with EMD Millipore—the Life Science division of Merck KGaA, Darmstadt, Germany. This long-term agreement strengthens the partnership and facilitates development of life science and protein assays by EMD Millipore for Luminex's flexible platform.


"We are very pleased to extend our global supply and distribution agreement with EMD Millipore, a leader in life science and protein research," said Michael F. Pintek , senior vice president of operations at Luminex. "EMD Millipore's broad selection of protein biomarkers in diverse research areas such as cancer, cell signaling, cellular metabolism, and immunology reflects their leadership in the life science research market. Together we can accelerate the pace of research and advance healthcare for people around the world."

As part of the agreement, EMD Millipore will continue to offer the full range of Luminex's xMAP® systems, including MAGPIX®, Luminex® 100/200™, and FLEXMAP 3D®. Luminex Technology is widely supported and validated across both clinical and life science research markets, with cumulative shipments to date nearing 10,000 total instruments and over 16,000 publications across a broad spectrum of applications. 

"EMD Millipore is committed to continue bringing to researchers the largest selection of assays and analytes for Luminex's instrument portfolio," said John Sweeney , head of life sciences business at EMD Millipore. "This renewal of our partnership with Luminex ensures that EMD Millipore can provide customers with a complete solution for multiplexed protein detection—encompassing assay kits, instruments, software and services—that will support them over the years."

EMD Millipore, a leader in multiplex assay kit development, has continued to push into emerging areas of research and recently announced the availability of MILLIPLEX® map human stem cell pluripotency kits and MILLIPLEX® map kits for cellular metabolism. Compared with traditional biomarker detection techniques such as western blots, these new kits increase assay throughput and specificity. Additionally, EMD Millipore recently released the newest version of their best-in-class multiplex data analysis package, MILLIPLEX® Analyst 5.1 software—one of the most robust data analysis tools available today for Luminex® platform-based multiplexed immunoassays.  

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture—multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies—that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award-winning technology, please visit


Luminex Investor Contact:
Matthew Scalo , 512.219.8020
Sr. Director Investor Relations

Luminex Media Contact:
Mimi Torrington , 512.219.8020
Director of Marketing Communications



SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation To Present At Upcoming Investment Conferences
2. Luminex Corporation Reports First Quarter 2013 Results
3. Luminex Corporation First Quarter Earnings Release Scheduled for April 29, 2013
4. Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results
5. Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
6. Luminex Corporation Reports Third Quarter 2012 Results
7. Luminex Corporation To Present At Upcoming Investment Conferences In September
8. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
9. Luminex Corporation Recognized as Best Technology Company in Austin
10. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
11. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
Post Your Comments:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):